Search company, investor...

ForSight VISION4

Founded Year

2005

Stage

Acquired | Acquired

Total Raised

$8.4M

About ForSight VISION4

ForSight Labs is a community of ophthalmic innovation focused on developing and applying solutions to improve the sight, care, and quality of life of visually impaired patients.

Headquarters Location

191 Jefferson Drive

Menlo Park, California, 94025,

United States

650-325-2050

Missing: ForSight VISION4's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: ForSight VISION4's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

ForSight VISION4 Patents

ForSight VISION4 has filed 63 patents.

The 3 most popular patent topics include:

  • Diseases of the eye and adnexa
  • Ophthalmology
  • Amines
patents chart

Application Date

Grant Date

Title

Related Topics

Status

7/17/2019

11/29/2022

Disorders of sclera and cornea, Diseases of the eye and adnexa, Pharmacokinetics, Ophthalmology, Visual system

Grant

Application Date

7/17/2019

Grant Date

11/29/2022

Title

Related Topics

Disorders of sclera and cornea, Diseases of the eye and adnexa, Pharmacokinetics, Ophthalmology, Visual system

Status

Grant

Latest ForSight VISION4 News

ForSight VISION4, Inc. Announces Acquisition by Roche

Jan 16, 2017

Announces Acquisition by Roche Next Story Prev Story 1 hr ago Read more: Vision Monday MENLO PARK, Calif.-ForSight VISION4, a privately held biotechnology company innovating drug delivery for treatment of retinal diseases, announced that it has been acquired by Roche Holdings Inc. The company is the fourth venture created by the Menlo Park incubator, ForSight Labs, LLC , and was funded entirely by two of the leading venture capital firms in Silicon Valley, Morgenthaler Ventures and Versant Ventures. The acquisition expands Roche's exclusive access to the ForSight VISION4 PDS technology for long acting delivery of therapeutics to the eye. Start the conversation, or Read more at Vision Monday.

ForSight VISION4 Frequently Asked Questions (FAQ)

  • When was ForSight VISION4 founded?

    ForSight VISION4 was founded in 2005.

  • Where is ForSight VISION4's headquarters?

    ForSight VISION4's headquarters is located at 191 Jefferson Drive, Menlo Park.

  • What is ForSight VISION4's latest funding round?

    ForSight VISION4's latest funding round is Acquired.

  • How much did ForSight VISION4 raise?

    ForSight VISION4 raised a total of $8.4M.

  • Who are the investors of ForSight VISION4?

    Investors of ForSight VISION4 include Roche Holding, Versant Ventures, Morgenthaler Ventures, Split Rock Partners and The Foundry.

  • Who are ForSight VISION4's competitors?

    Competitors of ForSight VISION4 include Biocytogen, Biolog, Bloomage BioTech, Biodel, Seahorse Bioscience and 12 more.

Compare ForSight VISION4 to Competitors

Biolog Logo
Biolog

Biolog specializes in microbial identification, phenotypic cell profiling, and metabolic fingerprinting for microbial and mammalian cells. The company’s products enable the identification of thousands of species of bacteria, yeast, and fungi, as well as the characterization of human cells and mitochondria. Biolog's products are available worldwide, either directly from the company or through its extensive network of international distributors. The company was founded in 1984 and is based in Hayward, California.

P
Protherics plc

Protherics is an international biopharmaceutical company focused on specialist products for critical care and cancer.nThe Company has two critical care products, CroFab and DigiFab, approved for sale in the US. The Company has the opportunity to sell these products in the US from October 2010 together with Voraxaze, a supportive cancer care product, following anticipated approval in the US in 2010. Protherics is also developing a number of other products in the cancer arena that it can commercialise in-house.nIn addition, Protherics has several potential blockbuster products that require development and commercialisation partners. These include CytoFab which has been partnered by AstraZeneca in a major licensing deal, and also Angiotensin Therapeutic Vaccine and Digoxin Immune Fabs for which licensing partners will be sought in 2008-2009. These products have the potential to be high value products that can provide additional funding for the Company.n

A
Angel Biotechnology

Angel Biotechnology Holdings PLC (AIM: ABH) is a world class, contract biomanufacturing company offering process development services and pre-GMP and cGMP manufacturing to support biotechnology and pharmaceutical companies worldwide. Angel's principal activity is the manufacture and supply of materials for use in early stage drug development and pre-clinical studies, along with drug product and CMC documentation for Phases I, II and III clinical trials and the manufacture of licensed drugs or vaccines. nnAngel is managed by a team that has more than 100 years' combined experience in pharmaceutical and biopharmaceutical manufacture, gained in companies such as Glaxo and Serologicals Inc. nnAngel operates out of Pentlands Science Park, near Edinburgh.

S
Sensia Biosensing Solutions

April 2004, Sensia spun-off from the technologies developed at the Biosensor Group within the National Microelectronics Centre (CNM) of the Spanish National Research Council (CSIC). Concluding research results and availability of biosensing systems already working at lab level originated the proposal of bringing them into commercialisation, after an initial phase of prototyping and industrialisation. This first idea was supported by Genetrix a young biotech company which is interested in developing biosensors for the characterisation and detection of molecular interactions which are relevant in human pathologies. Dr. Pedro Banda, with experience in the semiconductor industry and biosensor technologies, joined in to get in charge of the project.n

d
deltaDOT

deltaDOT Ltd is a life science company that is developing and commercialising enabling technologies for the separation and analysis of biomolecules. It was founded in 2000 and is a spin out from Imperial College of Science, Technology and Medicine, London. deltaDOT's core label free analysis technology, coupled with software algorithms, forms the technical basis of its products. This label free technology aims to enable higher quality and faster separations compared to existing technologies. The increased performance aims to enable the direct monitoring of unlabelled biomolecules, reducing the cost per analysis compared to conventional methods. deltaDOT addresses biomolecular separation applications within pharmaceutical, biotechnology, biodefence, food and drink quality, forensic science, diagnostic and academic markets. The London Technology Fund participated in a funding round of £6m in March 2006.

C
CELBIO SpA

SiTec Consulting was established in 1996, on the basis of long experience in pharmaceutical R&D. The company developed a range of expertise working with pharmaceutical and biotech companies in the United States and in Europe.n SiTec Consulting offers pharmaceutical and biotechnology companies a variety of services in the areas of preformulation, drug development, drug delivery and formulation technologies evaluation, regulatory and cGLP/cGMP compliance. The company can actively collaborate with start-up pharmaceutical and drug delivery companies to provide scientific and strategic support in the establishment of the new company's activities. The company emphasize open communication, active involvement with the client and continuous feedback.n Networking is one of the company's assets, allowing us to cover the complex demands of the R&D process. The company have access to laboratories and equipment and resources, located at the Bioindustry Park Canavese, and at selected universities and research centers in Europe. This aims to give the possibility to conduct and manage experimental parts of projects at the company's clients' request.n The company value the importance of high quality training. In addition to the hands-on experience the company can provide to the company's clients, SiTec is an authorized representative of the Center for Professional Advancement, a worldwide private institution dedicated to the provision of continuing technical and scientific education at a professional level.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.